Travere Therapeutics (NASDAQ:TVTX) Given "Overweight" Rating at Cantor Fitzgerald

Travere Therapeutics (NASDAQ:TVTX - Get Free Report)'s stock had its "overweight" rating restated by equities researchers at Cantor Fitzgerald in a report issued on Thursday,Benzinga reports.

A number of other analysts have also commented on TVTX. Scotiabank lifted their price objective on Travere Therapeutics from $27.00 to $32.00 and gave the stock a "sector outperform" rating in a research report on Wednesday, February 12th. Bank of America lifted their price objective on Travere Therapeutics from $29.00 to $31.00 and gave the stock a "buy" rating in a research note on Tuesday, April 1st. Canaccord Genuity Group increased their target price on Travere Therapeutics from $22.00 to $45.00 and gave the company a "buy" rating in a research note on Wednesday, February 12th. HC Wainwright boosted their target price on Travere Therapeutics from $18.00 to $22.00 and gave the stock a "buy" rating in a research report on Wednesday, January 15th. Finally, Citigroup increased their price target on shares of Travere Therapeutics from $31.00 to $35.00 and gave the company a "buy" rating in a research report on Monday, February 24th. One equities research analyst has rated the stock with a hold rating and thirteen have given a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $31.46.

Travere Therapeutics Price Performance

TVTX traded down $0.92 during midday trading on Thursday, hitting $14.25. The company had a trading volume of 517,474 shares, compared to its average volume of 1,505,837. Travere Therapeutics has a twelve month low of $5.12 and a twelve month high of $25.29. The company has a market capitalization of $1.26 billion, a PE ratio of -3.48 and a beta of 0.84. The company has a debt-to-equity ratio of 24.96, a quick ratio of 1.68 and a current ratio of 1.71. The firm's 50-day simple moving average is $20.39 and its 200-day simple moving average is $18.64.

Remove Ads

Travere Therapeutics (NASDAQ:TVTX - Get Free Report) last released its quarterly earnings results on Thursday, February 20th. The company reported ($0.73) EPS for the quarter, missing the consensus estimate of ($0.58) by ($0.15). Travere Therapeutics had a negative net margin of 137.90% and a negative return on equity of 1,636.87%. The company had revenue of $74.79 million for the quarter, compared to the consensus estimate of $72.38 million. Equities research analysts predict that Travere Therapeutics will post -1.4 EPS for the current fiscal year.

Insider Transactions at Travere Therapeutics

In related news, CFO Christopher R. Cline sold 5,192 shares of Travere Therapeutics stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $20.12, for a total value of $104,463.04. Following the sale, the chief financial officer now owns 90,038 shares of the company's stock, valued at approximately $1,811,564.56. This trade represents a 5.45 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Peter Heerma sold 1,584 shares of the company's stock in a transaction that occurred on Wednesday, January 22nd. The stock was sold at an average price of $18.94, for a total value of $30,000.96. Following the transaction, the insider now directly owns 106,374 shares of the company's stock, valued at approximately $2,014,723.56. This trade represents a 1.47 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 188,829 shares of company stock valued at $4,146,997 over the last quarter. Corporate insiders own 3.75% of the company's stock.

Institutional Trading of Travere Therapeutics

A number of institutional investors have recently made changes to their positions in the business. GF Fund Management CO. LTD. bought a new position in Travere Therapeutics in the fourth quarter valued at $31,000. Sterling Capital Management LLC boosted its stake in shares of Travere Therapeutics by 859.8% during the 4th quarter. Sterling Capital Management LLC now owns 2,361 shares of the company's stock worth $41,000 after buying an additional 2,115 shares during the last quarter. R Squared Ltd bought a new position in shares of Travere Therapeutics in the 4th quarter valued at about $53,000. Gen Wealth Partners Inc bought a new position in Travere Therapeutics in the fourth quarter valued at approximately $73,000. Finally, Quarry LP acquired a new position in shares of Travere Therapeutics during the 3rd quarter worth approximately $105,000.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.